Editas Medicine (NASDAQ:EDIT) reported fourth-quarter results on Monday that significantly outpaced Wall Street projections, fueled by higher collaboration revenue and a sharp reduction in operating expenses.
The Cambridge, Massachusetts-based pioneer in gene editing narrowed its quarterly net loss to $5.6 million, a major improvement from the $45.4 million loss recorded in the same period a year ago.
Following the transition to a leaner, in vivo-focused strategy, the company confirmed its cash position is sufficient to fund operations well into 2027.
The genome editing specialist posted revenue of $24.7 million for the quarter ended December 31, 2025, a figure that nearly quadrupled the $6.5 million average estimate from analysts surveyed by Zacks Investment Research.
The revenue spike was primarily driven by the recognition of milestone payments under existing strategic collaborations, including its partnership with Bristol Myers Squibb.
On a per-share basis, Editas reported a loss of 6 cents, substantially better than the 27-cent loss anticipated by the market.
This financial discipline follows the company’s December 2024 decision to discontinue its reni-cel program, a move that lowered research and development expenses to $27.4 million for the quarter—a $21.2 million decrease year-over-year.